About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Oral Antibiotic Therapy Benefits Infectious Endocarditis Patients

by Colleen Fleiss on March 20, 2019 at 6:23 AM
Font : A-A+

Oral Antibiotic Therapy Benefits Infectious Endocarditis Patients

Oral antibiotic therapy was found to be safe and effective in patients with an infection of the inner lining on the left side of the heart (endocarditis), according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

While initial six-month data had shown that partial treatment with oral antibiotics was similar in efficacy and safety to conventional intravenous therapy for left-sided infectious endocarditis, longer follow-up (median of 3.5 years) demonstrates this therapeutic approach is better for patients, said Henning Bundgaard, MD, PhD, DMSc, professor of cardiology at the Heart Center at the National University Hospital in Copenhagen, Denmark, and the study's lead author.

Advertisement


People with pre-existing heart valve disease, previous endocarditis, prosthetic heart valves or other implanted cardiac devices have an elevated risk for infectious endocarditis. The condition most often occurs on the left side of the heart in the mitral or aortic valve. Men are diagnosed with infectious endocarditis about twice as often as women.

The current study, known as POET, is the largest randomized trial of patients with infectious endocarditis, and was designed to test whether oral antibiotic therapy for left-sided infectious endocarditis was at least as effective and safe as intravenous treatment.
Advertisement

Clinical guidelines from several professional organizations currently recommend treating left-sided infectious endocarditis with intravenous antibiotics for up to six weeks. During the initial treatment phase, patients often need intensive care and close monitoring. Because intravenous antibiotics are logistically difficult to administer outside of a hospital, most patients remain in the hospital for the duration of their treatment.

Studies have suggested that intravenous treatment during long hospital stays may put patients at increased risk for complications. Oral antibiotics would allow patients to leave the hospital sooner and complete their treatment at home. Studies in other conditions have shown that patients with shorter hospital stays generally had better outcomes.

A total of 400 patients (average age 67 years; 77 percent male) with left-sided infectious endocarditis were enrolled in the study. Study participants had to be in stable condition and to have had a satisfactory response to at least 10 days of intravenous antibiotic treatment before randomization. They were then randomly assigned to either continue with intravenous antibiotics or switch to oral treatment for an average of 17 days after they were diagnosed. Intravenously-treated patients remained in the hospital until they completed antibiotic therapy. Patients who switched to oral treatment were discharged from the hospital a median of three days after making the switch.

The study's primary endpoint was a composite of death from any cause, unplanned cardiac surgery, embolic events (e.g., stroke) and relapse of infection with the same pathogen from the time of randomization until the end of follow-up.

After a median of 3.5 years of follow-up, 53 patients (26.4 percent) in the group receiving partial oral treatment had a primary-endpoint event, compared with 76 patients (38.2 percent) in the intravenously treated group, a statistically significant difference. Eighty-seven patients died; of these, 54 (27.1 percent) were treated intravenously and 33 (16.4 percent) were treated with oral medications, a significant difference. No significant differences in outcome were seen for relapse of infection, unplanned cardiac surgery or embolic events. The magnitude of the difference between the two groups is sufficient to conclude that oral treatment is superior to intravenous treatment, Bundgaard said.

Only patients with left-sided infectious endocarditis caused by certain bacterial species were enrolled in the trial, Bundgaard said, and the results may not apply to the approximately 25 percent of patients whose conditions are caused by other bacteria. In addition, although patients with antibiotic-resistant bacteria were not excluded from the trial, none were enrolled. Bundgaard and his colleagues plan to conduct additional analyses to compare quality of life and treatment costs in the groups receiving intravenous and partial oral treatment.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Drug News

 FDA Issues Warning About Compounded Diabetes Drug Semaglutide Products
The FDA advises consumers not to use compounded medications as an alternative to known diabetic and weight reduction medications Ozempic, Rybelsus, and Wegovy.
 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Oral Antibiotic Therapy Benefits Infectious Endocarditis Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests